Document Detail


Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.
MedLine Citation:
PMID:  1350695     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The expression of the c-erbB-2 proto-oncogene product was investigated immunohistochemically in 474 formalin-fixed and paraffin-embedded human breast tissue samples. The series included 32 benign and 26 hyperplastic lesions, 32 carcinomas in situ and 384 invasive breast carcinomas, 107 of which were less than 1 cm in diameter. Cytometric DNA assessments were performed on histopathologically or cytodiagnostically identified cell nuclei, using image analysis. C-erbB-2 immunoreactivity was not seen in normal parenchyma or in benign and hyperplastic lesions. Mammary carcinomas in situ were more frequently immunoreactive (59%) than invasive neoplasms (23%). Invasive tumours more than 1 cm in diameter immunoreacted more often (26%) than small invasive carcinomas (16%). C-erbB-2 expression in regional lymph node metastases was the same as in the corresponding primary tumours. Significant differences were observed between the c-erbB-2 expression in DNA diploid and aneuploid lesions; for carcinomas in situ the figures were 40% and 72%, respectively. Invasive carcinomas of DNA diploid type rarely showed c-erb-B-2 expression, irrespective of tumour size and nodal status (7-11%). DNA aneuploid tumours were more frequently immunoreactive with increasing levels during progression (32-41%). Our data indicate that genetically stable invasive mammary tumours seem rarely to express the c-erbB-2 protein, even during progression, whereas genetically unstable invasive neoplasms frequently show c-erbB-2 immunoreactivity which increases during tumour progression.
Authors:
H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Related Documents :
20592365 - Cea-, her2/neu-, bcrp- and hsp27-positive microparticles in breast cancer patients.
2286355 - Factor x-activating procoagulant in normal and malignant breast tissue.
2702455 - Characterization of breast cancer subgroups in an african population.
3828255 - Tumour-associated monoclonal antibodies for the diagnosis and assessment of ovarian can...
17343345 - Anne of austria (1601-1666), queen of france: died of breast cancer.
2347415 - Static and flow cytometric dna analysis compared to histologic prognostic factors in a ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Virchows Archiv. A, Pathological anatomy and histopathology     Volume:  420     ISSN:  0174-7398     ISO Abbreviation:  Virchows Arch A Pathol Anat Histopathol     Publication Date:  1992  
Date Detail:
Created Date:  1992-06-30     Completed Date:  1992-06-30     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8302198     Medline TA:  Virchows Arch A Pathol Anat Histopathol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  433-40     Citation Subset:  IM    
Affiliation:
Department of Tumour Pathology, Karolinska Institute and Hospital, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast / metabolism*
Breast Diseases / metabolism*
Breast Neoplasms / metabolism*,  pathology
Cell Nucleus / metabolism*
DNA, Neoplasm / metabolism*
Humans
Immunohistochemistry
Lymphatic Metastasis
Neoplasm Invasiveness
Proto-Oncogene Proteins / metabolism*
Proto-Oncogenes
Receptor, erbB-2
Chemical
Reg. No./Substance:
0/DNA, Neoplasm; 0/Proto-Oncogene Proteins; EC 2.7.10.1/Receptor, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Studies on maternal transmission of scrapie in sheep by embryo transfer.
Next Document:  Comparison of the effects of diltiazem and isradipine in adrenergic beta receptor blockade in patien...